IDEAYA Biosciences, Inc. announced the appointment of Stu Dorman as Chief Commercial Officer on November 18, 2024. Mr. Dorman brings over 20 years of oncology and hematology experience, with a track record of commercial success in specialty disease areas.
Prior to joining IDEAYA, Mr. Dorman served as Vice President, U.S. Oncology Business Unit Head at Gilead Sciences, where he built a leading oncology commercial organization and successfully launched Trodelvy in multiple indications. He also held positions at Bristol Myers Squibb, leading commercial strategy for Opdivo, Yervoy, and Abraxane.
This appointment is significant as IDEAYA continues to advance its potential registrational trial for darovasertib in first-line HLA-A2(-) metastatic uveal melanoma and explores indication expansion in neoadjuvant uveal melanoma. Mr. Dorman's expertise will be instrumental in building an industry-leading commercial organization for IDEAYA's precision medicine oncology therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.